A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis

J Dermatolog Treat. 2006;17(2):90-5. doi: 10.1080/09546630500515701.

Abstract

The clinical benefit of currently available tar blend shampoos for the treatment of scalp psoriasis is restricted due to their limited efficacy, low cosmetic appeal and potential for carcinogenicity. This 4-week multicentre, randomized, parallel-group, investigator-masked study included 162 subjects and aimed to compare the efficacy, safety and cosmetic acceptability of clobetasol propionate 0.05% shampoo versus a currently marketed tar blend 1% shampoo in subjects with moderate to severe scalp psoriasis. Clobetasol propionate shampoo was superior to tar blend shampoo with respect to all efficacy variables tested (p<0.001): Total and Global Severity Score; erythema; plaque thickening; desquamation; pruritus; total scalp area involved; and the subject's global assessment of clinical improvement. Both treatments were safe and well-tolerated. Furthermore, more subjects indicated that clobetasol propionate shampoo was more cosmetically acceptable than tar blend shampoo. Clobetasol propionate 0.05% shampoo is a good alternative to tar blend shampoo in the treatment of moderate to severe scalp psoriasis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Clobetasol / administration & dosage
  • Clobetasol / analogs & derivatives*
  • Double-Blind Method
  • Female
  • Hair Preparations
  • Humans
  • Keratolytic Agents / administration & dosage*
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Scalp Dermatoses / drug therapy*
  • Scalp Dermatoses / pathology
  • Severity of Illness Index
  • Tars
  • Treatment Outcome

Substances

  • Hair Preparations
  • Keratolytic Agents
  • Tars
  • Clobetasol